Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.815 · Cited by 792 · cited 4×
“…and conclusions are often made after the separation of the predictions according to the in vivo DDI potency, analogous to the approach proposed by the United States Food and Drug Administration guidelines for the classification of inhibitor potency (Bjornsson et al., 2003; Huang et al., 2007).”
BackgroundMethodInfluentialDrug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
Huang, S.-M., Temple, R., Throckmorton, D. C., & Lesko, L. J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100054 · Cited by 579
The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions
Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Gaman, E. A., Houston, J. B., & Tremaine, L. M. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093229 · Cited by 433 · cited 3×
“Therefore, the current study proposes an alternative method to assess prediction success with a variable prediction margin dependent on the particular AUC ratio.”
MethodSelf-citationRostami-Hodjegan, A., & Tucker, G. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.10.002 · Cited by 239 · cited 1×
“The commonly used metric to assess DDI is the ratio of the area under the plasma concentration-time curve (AUC) after multiple dosing of inhibitor or inducer in comparison to the control state (Rostami-Hodjegan and Tucker, 2004; Obach et al., 2006; Houston and Galetin, 2008; Fahmi et al., 2009).”
MethodSelf-citationFahmi, O. A., Hurst, S., Plowchalk, D., Cook, J., Guo, F., Youdim, K., Dickins, M., Phipps, A., Darekar, A., Hyland, R., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.026252 · Cited by 212 · cited 9×
“TABLE 2 Prediction accuracy of 89 DDI studies involving midazolam as the victim drug, collated from three publications (Einolf, 2007; Fahmi et al., 2009; Guest et al., 2010) Prediction accuracy is assessed by the following methods: the traditional two-fold measure, the new predictive measure, and…”
BackgroundMethodInfluentialMethods for Predicting In Vivo Pharmacokinetics Using Data from In Vitro Assays
Houston, J. B., & Galetin, A. (2008) · Current Drug Metabolism · doi:10.2174/138920008786485164 · Cited by 165 · cited 1×
“The commonly used metric to assess DDI is the ratio of the area under the plasma concentration-time curve (AUC) after multiple dosing of inhibitor or inducer in comparison to the control state (Rostami-Hodjegan and Tucker, 2004; Obach et al., 2006; Houston and Galetin, 2008; Fahmi et al., 2009).”
MethodSelf-citationGaletin, A., Burt, H., Gibbons, L., & Houston, J. B. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006874 · Cited by 160
Self-citationCYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions
Galetin, A., Ito, K., Hallifax, D., & Houston, J. B. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.082826 · Cited by 158 · cited 3×
“This study considers the importance of the two-fold criterion in the assessment of DDI prediction success.”
BackgroundMethodSelf-citationBrown, H. S., Galetin, A., Hallifax, D., & Houston, J. B. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645100-00006 · Cited by 139
Self-citationComparison of different approaches to predict metabolic drug-drug interactions
Einolf, H. J. (2007) · Xenobiotica · doi:10.1080/00498250701620700 · Cited by 130
Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions
Galetin, A., Gertz, M., & Houston, J. B. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.7.909 · Cited by 130
Self-citationWang, Y.-H. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032177 · Cited by 112 · cited 2×
“…the in vitro-in vivo extrapolation of either clearance or drug-drug interactions (DDI) accepts prediction within a two-fold (or occasionally three-fold) range from the observed data as successful (Galetin et al., 2005, 2006; Brown et al., 2006; Einolf, 2007; Teitelbaum et al., 2010; Wang, 2010).”
BackgroundMethodKharasch, E. D., Walker, A., Isoherranen, N., Hoffer, C. J., Sheffels, P. R., Thummel, K. E., Whittington, D., & Ensign, D. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100237 · Cited by 107 · cited 2×
“Assessment of the variability in the present study was based on approximately 20% CV reported for midazolam AUC (Kharasch et al., 1999, 2007) after intravenous dosing.”
MethodResultEvaluation of Bioequivalence for Highly Variable Drugs with Scaled Average Bioequivalence
Tóthfalusi, L., Endrényi, L., & García‐Arieta, A. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318040-000000000-00000 · Cited by 104 · cited 2×
“Thus, the study proposes a more logical method for the assessment of prediction success and its application for induction and inhibition DDIs.”
BackgroundMethodMaraviroc:in vitro assessment of drug–drug interaction potential
Hyland, R., Dickins, M., Collins, C., Jones, H., & Jones, B. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03198.x · Cited by 90 · cited 2×
“negative DDI (AUC ratio 2), and therefore the decision on future follow-up clinical DDI trials will be based on the small scale studies and/or prediction from in vitro data using DDI models or prediction software such as Simcyp simulator (Hyland et al., 2008; Zhao et al., 2010).”
MethodGuest, E. J., Yeo, K. R., Rostami‐Hodjegan, A., Tucker, G. T., Houston, J. B., & Galetin, A. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03799.x · Cited by 77 · cited 4×
“To assess the new predictive measure, DDI predictions were collated from three publications (Einolf, 2007; Fahmi et al., 2009; Guest et al., 2010) focusing on the prediction of DDIs involving midazolam as the victim drug.”
BackgroundMethodInfluentialSelf-citationKharasch, E. D., Jubert, C., Senn, T., Bowdle, A. T., & Thummel, K. E. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008290 · Cited by 50 · cited 2×
“Assessment of the variability in the present study was based on approximately 20% CV reported for midazolam AUC (Kharasch et al., 1999, 2007) after intravenous dosing.”
MethodResultRisk Assessment in Extrapolation of Pharmacokinetics from Preclinical Data to Humans
Teitelbaum, Z., Lavé, T., Freijer, J. I., & Cohen, A. F. (2010) · Clinical Pharmacokinetics · doi:10.2165/11533760-000000000-00000 · Cited by 15 · cited 2×
“…the in vitro-in vivo extrapolation of either clearance or drug-drug interactions (DDI) accepts prediction within a two-fold (or occasionally three-fold) range from the observed data as successful (Galetin et al., 2005, 2006; Brown et al., 2006; Einolf, 2007; Teitelbaum et al., 2010; Wang, 2010).”
BackgroundMethodPoster Session III (PIII 1-84)Displayed 8:00 am – 12:45 pmAttended 8:00 am – 9:30 am
(2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.277 · Cited by 4
Cited by
Shebley, M., Sandhu, P., Emami Riedmaier, A., Jamei, M., Narayanan, R., Patel, A., Peters, S. A., Reddy, V. P., Zheng, M., de Zwart, L., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1013 · Cited by 395
Hanke, N., Frechen, S., Moj, D., Britz, H., Eissing, T., Wendl, T., & Lehr, T. (2018) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12343 · Cited by 169
Wagner, C., Pan, Y., Hsu, V., Grillo, J. A., Zhang, L., Reynolds, K. S., Sinha, V., & Zhao, P. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0188-4 · Cited by 148
“[8] that the 2-fold criterion may result in potential bias towards successful prediction of mild DDI (i.”
BackgroundInfluentialAlmond, L. M., Mukadam, S., Gardner, I., Okialda, K., Wong, S., Hatley, O., Tay, S., Rowland-Yeo, K., Jamei, M., Rostami-Hodjegan, A., et al. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.066845 · Cited by 101
Self-citationWojtyniak, J., Selzer, D., Schwab, M., & Lehr, T. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2111 · Cited by 38
Metadata
- Authors
- Guest, E. J., Aarons, L., Houston, J. B., Rostami-Hodjegan, A., & Galetin, A.
- Venue
- Drug Metabolism and Disposition
- Publisher
- Elsevier BV
- Published
- 2011-02
- Volume
- 39
- Issue
- 2
- Pages
- 170-173
- ISSN
- 0090-9556 (ISSN-L)
- OpenAlex
- W2156841554
- Cited by
- 199
- References
- 19
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.